A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Recruiting · NCT07516951 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-09-17 | NCT07516951 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chiesi Farmaceutici S.p.A. | 24 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hannibal Regional Healthcare System, Inc. | Hannibal | United States | 3 |
| PHI University Clinic of Pulmonology and Allergology | Skopje | North Macedonia | 1 |
| Premier Pulmonary Critical Care and Sleep Medicine, PA | Denison | United States | 1 |